

Table S2 Amount of change in serum urate level at the final visit from the level at baseline (FAS)

Group	n	Amount changes of serum urate level ($\mu\text{mol/L}$)		
		mean \pm SD	Statistics Tukey	
P	35	-22.4 ± 63.6	P vs 120	$P < 0.001^*$
			P vs 160	$P < 0.001^*$
120	39	-220.8 ± 64.7	120 vs 160	$P = 0.559$
160	39	-243.0 ± 82.1	Allo vs P	$P < 0.001^*$
			Allo vs 120	$P = 0.986$
Allo	38	-226.7 ± 84.9	Allo vs 160	$P = 0.773$

* : $P < 0.05$

P: Placebo group

120: Topiroxostat 120 mg group

160: Topiroxostat 160 mg group

Allo: Allopurinol group

Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study

Submitted to Clinical Rheumatology

Authors: Tatsuo Hosoya, Tomomitsu Sasaki, Tetsuo Ohashi

Corresponding author: Tomomitsu Sasaki

Development Department, Medical R&D Division, Fuji Yakuhin Co., Ltd.

tomomitsu@fujiyakuhin.co.jp